Quince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Brookline Capital Management

Brookline Capital Management began coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a report published on Wednesday morning,Benzinga reports. The brokerage issued a buy rating and a $9.00 price objective on the stock.

QNCX has been the subject of a number of other reports. Maxim Group began coverage on shares of Quince Therapeutics in a research report on Thursday, November 7th. They set a “buy” rating and a $6.00 target price for the company. Rodman & Renshaw began coverage on shares of Quince Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $11.00 target price for the company. EF Hutton Acquisition Co. I upgraded shares of Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, RODMAN&RENSHAW upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $8.67.

Quince Therapeutics Trading Up 0.5 %

NASDAQ:QNCX opened at $1.85 on Wednesday. The firm has a fifty day simple moving average of $1.57 and a 200-day simple moving average of $1.02. Quince Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.45. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $81.40 million, a P/E ratio of -1.49 and a beta of 0.74.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Quince Therapeutics stock. Geode Capital Management LLC grew its position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 339,125 shares of the company’s stock after purchasing an additional 66,170 shares during the period. Geode Capital Management LLC owned approximately 0.78% of Quince Therapeutics worth $263,000 as of its most recent SEC filing. 30.75% of the stock is owned by hedge funds and other institutional investors.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.